Article citationsMore>>

Hess, D.A., Terenzi, D.C., Trac, J.Z., Quan, A., Mason, T., Al-Omran, M., et al. (2019) SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. Cell Metabolism, 30, 609-613.
https://doi.org/10.1016/j.cmet.2019.08.015

has been cited by the following article:

• TITLE: SGLT-2 Inhibitors: The Magic Bullet for Cardio-Renal Protection in Type 2 DM

  AUTHORS: Rushi Patel, Terry Oroszi

  KEYWORDS: SGLT-2 Inhibitors, Type 2 Diabetes Mellitus, Cardiovascular Outcomes, Renal Protection, Glycemic Control

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.15 No.12, December 30, 2024

  ABSTRACT: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a promising class of medications for type 2 diabetes mellitus (DM2) treatment. This study aims to evaluate the clinical efficacy, safety, and potential benefits of SGLT-2 inhibitors in improving cardiovascular and renal outcomes in DM2 patients. A comprehensive review of clinical trials and studies on SGLT-2 inhibitors was conducted. SGLT-2 inhibitors significantly improve glycemic control, reduce cardiovascular mortality, and lower the risk of renal events in DM2 patients. SGLT-2 inhibitors offer substantial cardio-renal protection in DM2 management, though further research is needed to optimize their use.